Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.
P de Knijff, … , R R Frants, L M Havekes
P de Knijff, … , R R Frants, L M Havekes
Published September 1, 1994
Citation Information: J Clin Invest. 1994;94(3):1252-1262. https://doi.org/10.1172/JCI117443.
View: Text | PDF
Research Article

Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

  • Text
  • PDF
Abstract

Genetic and biochemical studies were carried out in 96 relatives of six independently ascertained probands with familial dysbetalipoproteinemia (FD) carrying the APOE*2 (Lys146-->Gln) allele. Compared to noncarriers, the 40 heterozygous APOE*2 (Lys146-->Gln) allele carriers exhibited markedly increased mean levels of cholesterol and triglyceride in the very low density lipoproteins (VLDL) (1.89 +/- 0.37 vs 0.30 +/- 0.27 and 1.86 +/- 0.37 vs 0.68 +/- 0.27 mmol/liter, respectively) and plasma apolipoprotein (apo) E levels (28.1 +/- 1.6 vs 4.6 +/- 1.1 mg/dl), which is characteristic for FD. By means of a pedigree-based maximum likelihood method we calculated that carrier-status accounted for 57% and 71%, respectively, of the total variance of the ratio (VLDL + IDL)-cholesterol/plasma triglyceride and plasma apoE levels. APOE*2 (Lys146-->Gln) and APOE*3-Leiden allele carriers were found to differ significantly in: (a) plasma apoE levels, (b) in the amounts of triglycerides in the VLDL and VLDL + IDL fraction, and (c) in the amount of cholesterol in the VLDL and VLDL + IDL fraction relative to the amount of triglyceride in these fractions. In the APOE*2 (Lys146-->Gln) allele carriers the VLDL and VLDL + IDL fraction is relatively rich in triglycerides as compared with that in APOE*3-Leiden carriers. We hypothesize that these two rare mutations of apoE both lead to dominantly inherited forms of FD along different underlying metabolic defects.

Authors

P de Knijff, A M van den Maagdenberg, D I Boomsma, A F Stalenhoef, A H Smelt, J J Kastelein, A D Marais, R R Frants, L M Havekes

×

Total citations by year

Year: 2022 2016 2015 2003 2002 2001 2000 1999 1998 1997 1996 Total
Citations: 1 1 1 1 1 1 1 4 2 1 2 16
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (16)

Title and authors Publication Year
Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.
Heidemann BE, Koopal C, Baass A, Defesche JC, Zuurbier L, Mulder MT, Roeters van Lennep JE, Riksen NP, Boot C, Marais AD, Visseren FLJ
Clinical Genetics 2022
Autosomal dominant familial dysbetalipoproteinemia: A pathophysiological framework and practical approach to diagnosis and therapy
C Koopal, AD Marais, J Westerink, FL Visseren
Journal of Clinical Lipidology 2016
Role of apolipoprotein E in neurodegenerative diseases
VV Giau, E Bagyinszky, SS An, SY Kim
Neuropsychiatric Disease and Treatment 2015
Apolipoprotein ε2/3 genotype and type III hyperlipoproteinemia among Taiwanese
HP Lin, JT Kao
Clinica Chimica Acta 2003
Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia
M Dam, M Zwart, F Beer, AH Smelt, MH Prins, MD Trip, LM Havekes, PJ Lansberg, JJ Kastelein
Heart (British Cardiac Society) 2002
Molecular genetics and gene expression in atherosclerosis
PA Doevendans, W Jukema, W Spiering, JC Defesche, JJ Kastelein
International Journal of Cardiology 2001
Apolipoprotein E2 (Lys146→Gln) Causes Hypertriglyceridemia due to an Apolipoprotein E Variant–Specific Inhibition of Lipolysis of Very Low Density Lipoproteins–Triglycerides
F de Beer, KW van Dijk, MC Jong, LC van Vark, A van der Zee, MH Hofker, FJ Fallaux, RC Hoeben, AH Smelt, LM Havekes
Arteriosclerosis, thrombosis, and vascular biology 2000
Application of electrophoretic techniques to the diagnosis of disorders of lipoprotein metabolism. Examples at the levels of lipoproteins and apolipoproteins
W Groß, W März
Analytica Chimica Acta 1999
Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes
RW Mahley, Y Huang, SC Rall
Journal of lipid research 1999
Relevance of Apolipoprotein E Polymorphism for Coronary Artery Disease in the Saudi Population
N Dzimiri, BF Meyer, SS Hussain, C Basco, B Afrane, Z Halees
Archives of pathology & laboratory medicine 1999
Dissection of the complex role of apolipoprotein E in lipoprotein metabolism and atherosclerosis using mouse models
KW van Dijk, MH Hofker, LM Havekes
Current Atherosclerosis Reports 1999
GENETICS OF LIPOPROTEIN DISORDERS
J Davignon, J Genest
Endocrinology & Metabolism Clinics of North America 1998
Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase
FH de Man, F Beer, A der Laarse, AH Smelt, JA Leuven, LM Havekes
Atherosclerosis 1998
The Apolipoprotein E2(Arg145Cys) Mutation Causes Autosomal Dominant Type III Hyperlipoproteinemia With Incomplete Penetrance
WJ de Villiers, DR van der Westhuyzen, GA Coetzee, HE Henderson, AD Marais
Arteriosclerosis, thrombosis, and vascular biology 1997
Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice
BJ van Vlijmen, HB van Hof, MJ Mol, H der Boom, A der Zee, RR Frants, MH Hofker, LM Havekes
Journal of Clinical Investigation 1996
Apolipoprotein E1-Hammersmith (Lys146 → Asn;Arg147 → Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia
MJ Hoffer, S Niththyananthan, RP Naoumova, MS Kibirige, RR Frants, LM Havekes, GR Thompson
Atherosclerosis 1996

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts